All News

Advancements in cancer therapy have improved survival time for patients with non-small cell lung cancer (NSCLC), according to a new study published in the Journal of Thoracic Oncology.

Controlling the viral reaction of cells latently infected with HIV may have implications for future drug treatments.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

A substantial portion of mortality from liver cirrhosis and hepatocellular carcinoma can be attributed to the extrahepatic manifestations associated with hepatitis C virus.

Lupin Pharmaceuticals, Inc. has voluntarily recalled 42 of lots of Ceftriaxone for Injection, USP products at the hospital/physician level. These products were found to contain visual grey particulate matter in reconstituted vials.

How can pharmacists implement nonpharmacologic treatments for patients with dementia?

Advancements in targeted therapies have helped significantly improve survival in late-stage anaplastic lymphoma kinase positive non-small cell lung cancer.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

The FDA approved cannabidiol (CBD) last year for the treatment of seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged 2 years and older. As pharmacists, we will likely be called upon as experts in CBD therapeutics.

Making the patients’ lives easier is at the heart of my job.

Top news of the week from Specialty Pharmacy Times.

Study finds that treating hepatitis C reduced the risk of developing the signs and symptoms of Parkinson disease.

A recall of Torrent Pharmaceuticals Limited’s Losartan Potassium Tablets USP has been expanded to include 8 additional lots. A total of 10 lots are now being recalled at the consumer level, including 2 recalled lots initially announced December 20, 2018.

New high-cost gene therapies are pushing health care providers to explore new methods to help the US health care system to fund specialty drugs.

The health insurance industry cautioned the Trump administration against allowing health reimbursement accounts (HRAs) to be used to purchase short-term limited duration health plans, in comments submitted regarding a proposed rule change.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.